Assessing HER2 Status Across Tumor Types

Video content above is prompted by the following:

• How do HER2 mutations differ from HER2 overexpression and gene amplification in terms of their impact on cancer?
  • How can this differ among cancer types?
• What are the incidences of HER2 overexpression across solid tumors? HER2 mutations?
• What is your current practice for testing for HER2? What testing methodologies are used? How do they differ and what can you learn from each?
  • What is the difference between HER2 amplification and IHC score? What are best practices to ensure patients with HER2 amplification aren’t missed?
  • Does this vary among solid tumors?
  • How have levels of HER2 expression changed? What percent of patients typically have HER2-low expression?
• Is what is known about HER2 expression/mutations from research in breast and other cancer types applicable to other solid tumor types? Are there unique aspects to consider?
• How might current understanding of HER2 expression and HER2 mutations in other solid tumors contribute to the development of future targeted therapies or personalized treatment approaches?